Reviewing Xencor Inc. (XNCR)’s and ImmuCell Corporation (NASDAQ:ICCC)’s results

Both Xencor Inc. (NASDAQ:XNCR) and ImmuCell Corporation (NASDAQ:ICCC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xencor Inc. 152.54M 11.57 39.13M -1.35 0.00
ImmuCell Corporation 12.52M 3.82 1.96M -0.42 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Xencor Inc. and ImmuCell Corporation.


Table 2 represents Xencor Inc. (NASDAQ:XNCR) and ImmuCell Corporation (NASDAQ:ICCC)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xencor Inc. 25.65% 7.2% 6.4%
ImmuCell Corporation -15.65% -10.2% -7%

Risk and Volatility

A 1.33 beta indicates that Xencor Inc. is 33.00% more volatile compared to Standard & Poor’s 500. In other hand, ImmuCell Corporation has beta of 1.18 which is 18.00% more volatile than Standard & Poor’s 500.


Xencor Inc.’s Current Ratio is 6.7 while its Quick Ratio is 6.7. On the competitive side is, ImmuCell Corporation which has a 2.5 Current Ratio and a 1.6 Quick Ratio. Xencor Inc. is better positioned to pay off short and long-term obligations compared to ImmuCell Corporation.

Analyst Recommendations

The table given features the ratings and recommendations for Xencor Inc. and ImmuCell Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Xencor Inc. 1 0 6 2.86
ImmuCell Corporation 0 0 0 0.00

$41 is Xencor Inc.’s average target price while its potential upside is 30.95%.

Insider & Institutional Ownership

The shares of both Xencor Inc. and ImmuCell Corporation are owned by institutional investors at 85.7% and 19.1% respectively. About 13.4% of Xencor Inc.’s share are owned by insiders. Competitively, insiders own roughly 4.9% of ImmuCell Corporation’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xencor Inc. 8.07% 6.75% -2.66% -8.13% 7.08% -3.76%
ImmuCell Corporation -3.75% -7.09% -13.6% -25.18% -12.87% -12.58%

For the past year Xencor Inc. was less bearish than ImmuCell Corporation.


On 10 of the 11 factors Xencor Inc. beats ImmuCell Corporation.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.